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Abstract This editorial article introduces a renaming of 
journal Exosomes and Microvesicles (EXMV) to the Journal 
of Circulating Biomarkers with a new editorial scope, 
mission and our approach for the upcoming year in 
relation to engaging at the international level, the 
translational art of the study of exosomes and 
microvesicles, and the interface between exosomes and 
microvesicles, circulating tumor cells, cell-free circulating 
DNA and circulating protein markers in precision 
medicine and drug development. There is a slight change 
in the members of the Editors in Chief, Editorial Board 
and extending collaborations to international societies, 
such as the American Society for Exosomes and 
Microvesicles (ASEMV). 
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In the past year, we have witnessed many excitements, 
exemplified by our sharp focus on engaging with 
international key opinion leaders, translational 
researchers and diagnostic and therapeutic innovators 
from both academia and industry working in the field of 
exosomes and microvesicles. We had hoped to leverage 
EXMV as a niche medium to showcase their latest 
research and advances, though we only received 13 
manuscripts and 10 of which were published requiring 
the service of 19 individual referees, we have decided to 
make significant changes to the existing journal. In order 
to achieve this goal we have decided to implement the 
following; we have invited a new member to join the 
EXMV Editors in Chief team, Dr. Shidong Jia (Bio 
available on the journal website). Dr. Jia is a Scientist at 
Genentech Inc. where he spearheads the biomarker 
development efforts in support of Oncology pipeline and 
drug-companion diagnostic co-development. Dr. Jia is an 
internationally recognized scientist in the extracellular 
vesicle field, among other circulating biomarkers and we 
look forward to working closely with him in bringing 
international exposure and success to the journal. And 
when considering the recent breakthrough in blood-based 
biomarker development, the new team of editors-in-
chiefs have decided to rename and re-index the journal 
name from EXMV to “Journal of Circulating Biomarkers” 
(abbreviated herein as JCB), and to expand the current 
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scope from exosomes and microvesicles to the interface 
between exosomes/microvesicles, circulating tumor cells, 
cell-free circulating DNA and circulating protein markers 
in the context of precision medicine and clinical drug 
development. New discoveries utilizing blood-based 
biomarkers will potentially enhance our understanding of 
the pathology and etiology of disease, particularly 
originating from the genetic and molecular world. The 
use of exosomes/microvesicles, circulating tumor cells, 
cell-free circulating DNA and circulating protein markers 
as a biomarker in clinical medicine for early diagnosis, 
prognosis and monitoring of therapy will be a significant 
advancement in the field. Significant progress has been 
accomplished up to this point, yet we hope this this new 
renamed journal will be the source to publish the process 
to the best clinical use of these new discoveries. 
As our first task, the Editors in Chief have and will 
actively expand our Editorial Board and develop 
collaborations/partnerships with international societies 
through conferences, meetings, webinars we will be 
attending, which will include scientific experts who 
understand how discovery moves from lab to the market 
and to attract contributors and participation from a more 
global audience. These experts will serve as the central 
hub of the circulating biomarker community for the latest 
advances and provide us guidance.  
The JCB manuscript processing and peer-review is entirely 
online. The Editorial Manager facilitates the manuscript 
processing time, reducing costs and is a better experience 
for our authors and reviewers. We have received 
numerous positive comments on this evolving electronic 
system, and we are indebted to our publisher, Intech, for 
managing this program for us. For more information, 
please visit our new manuscript submission system  
at http://www.editorialmanager.com/exo/default.asp. In 
addition, we are enforcing to expedite the acceptance to 
publishing time for our authors and will request informal 
opinions from our Editorial Board for borderline cases.  
JCB will continue to work on partnering with other 
scientific societies, academic and industry leaders to 
develop and advance the circulating biomarker field and 
to allow free access to knowledge. 
It’s our pleasure to thank the editorial team and 
publishers to make this journal possible.  
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